Skip to main content
Nature Communications logoLink to Nature Communications
. 2024 Jan 3;15:225. doi: 10.1038/s41467-023-44575-3

Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial

Nasser K Altorki 1,✉,#, Zachary H Walsh 2,#, Johannes C Melms 2, Jeffery L Port 1, Benjamin E Lee 1, Abu Nasar 1, Cathy Spinelli 1, Lindsay Caprio 2, Meri Rogava 2, Patricia Ho 2, Paul J Christos 3, Ashish Saxena 4, Olivier Elemento 5, Bhavneet Bhinder 5, Casey Ager 2, Amit Dipak Amin 2, Nicholas J Sanfilippo 6, Vivek Mittal 1, Alain C Borczuk 7, Silvia C Formenti 6, Benjamin Izar 2,8,9,, Timothy E McGraw 10,
PMCID: PMC10764801  PMID: 38172131

Correction to: Nature Communications 10.1038/s41467-023-44195-x, published online 19 December 2023

In this article, the author name Silvia C. Formenti was incorrectly written as Sylvia C. Formenti. The original article has been corrected.

Contributor Information

Nasser K. Altorki, Email: nkaltork@med.cornell.edu

Benjamin Izar, Email: bi2175@cumc.columbia.edu.

Timothy E. McGraw, Email: temcgraw@med.cornell.edu


Articles from Nature Communications are provided here courtesy of Nature Publishing Group

RESOURCES